Adverse event reporting in adult intensive care units and the impact of a multifaceted intervention on drug-related adverse events

被引:26
|
作者
Pagnamenta, Alberto [1 ,2 ]
Rabito, Giovanni [3 ]
Arosio, Alessandra [3 ]
Perren, Andreas [1 ,2 ]
Malacrida, Roberto [1 ,2 ]
Barazzoni, Fabrizio [4 ]
Domenighetti, Guido [1 ,2 ]
机构
[1] EOC, Dept Intens Care Med, Intens Care Units Reg Hosp Mendrisio, Bellinzona, Switzerland
[2] EOC, Dept Intens Care Med, Intens Care Units Reg Hosp Mendrisio, Lugano, Switzerland
[3] Reg Hosp Locarno, Div Qual Improvement & Risk Management, Locarno, Switzerland
[4] EOC, Med Area Unit, Bellinzona, Switzerland
来源
关键词
Adverse events; Medical errors; Patient safety; Quality improvement; Intensive care; Reliability; PATIENT SAFETY; QUALITY IMPROVEMENT; MEDICATION ERRORS; PHARMACISTS; FRAMEWORK; OUTCOMES;
D O I
10.1186/2110-5820-2-47
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Background: Adverse events (AEs) frequently occur in intensive care units (ICUs) and affect negatively patient outcomes. Targeted improvement strategies for patient safety are difficult to evaluate because of the intrinsic limitations of reporting crude AE rates. Single interventions influence positively the quality of care, but a multifaceted approach has been tested only in selected cases. The present study was designed to evaluate the rate, types, and contributing factors of emerging AEs and test the hypothesis that a multifaceted intervention on medication might reduce drug-related AEs. Methods: This is a prospective, multicenter, before-and-after study of adult patients admitted to four ICUs during a 24-month period. Voluntary, anonymous, self-reporting of AEs was performed using a detailed, locally designed questionnaire. The temporal impact of a multifaceted implementation strategy to reduce drug-related AEs was evaluated using the risk-index scores methodology. Results: A total of 2,047 AEs were reported (32 events per 100 ICU patient admissions and 117.4 events per 1,000 ICU patient days) from 6,404 patients, totaling 17,434 patient days. Nurses submitted the majority of questionnaires (n = 1,781, 87%). AEs were eye-witnessed in 49% (n = 1,003) of cases and occurred preferentially during an elective procedure (n = 1,597, 78%) and on morning shifts (n = 1,003, 49%), with a peak rate occurring around 10 a. m. Drug-related AEs were the most prevalent (n = 984, 48%), mainly as a consequence of incorrect prescriptions. Poor communication among caregivers (n = 776) and noncompliance with internal guidelines (n = 525) were the most prevalent contributing factors for AE occurrence. The majority of AEs (n = 1155, 56.4%) was associated with minimal, temporary harm. Risk-index scores for drug-related AEs decreased from 10.01 +/- 2.7 to 8.72 +/- 3.52 (absolute risk difference 1.29; 95% confidence interval, 0.88-1.7; p < 0.01) following the introduction of the intervention. Conclusions: AEs occurred in the ICU with a typical diurnal frequency distribution. Medication-related AEs were the most prevalent. By applying the risk-index scores methodology, we were able to demonstrate that our multifaceted implementation strategy focused on medication-related adverse events allowed to decrease drug related incidents.
引用
收藏
页数:10
相关论文
共 50 条
  • [31] Intravenous catheter-related adverse events exceed drug-related adverse events in outpatient parenteral antimicrobial therapy
    Underwood, Jonathan
    Marks, Michael
    Collins, Steve
    Logan, Sarah
    Pollara, Gabriele
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2019, 74 (03) : 787 - 790
  • [32] Drug-Related Keratitis: A Real-World FDA Adverse Event Reporting System Database Study
    Wu, Shi-Nan
    Chen, Xiao-Dong
    Zhang, Qing-He
    Wang, Yu-Qian
    Yan, Dan
    Xu, Chang-Sheng
    Wang, Shao-Pan
    Zhu, Linfangzi
    Qin, Dan-Yi
    Guo, Shu-Jia
    Chen, Lin
    Liu, Yu-Wen
    Huang, Caihong
    Hu, Jiaoyue
    Liu, Zuguo
    TRANSLATIONAL VISION SCIENCE & TECHNOLOGY, 2024, 13 (09):
  • [33] Risk factors for drug-related acute pancreatitis: an analysis of the FDA adverse event reporting system (FAERS)
    Zhang, Lin
    Mao, Wei
    Liu, Dan
    Hu, Bin
    Lin, Xiaofang
    Ran, Jie
    Li, Xingxing
    Hu, Jing
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [34] The quality of adverse event reporting in drug-related hemorrhagic stroke trials from the stroke trials registry
    Hussein, Haitham M.
    Baybutt, Trevor R.
    Zhou, Jingying
    Divani, Afshin A.
    Qureshi, Adnan I.
    STROKE, 2007, 38 (02) : 543 - 543
  • [35] Adverse events reported to the US Food and Drug Administration Adverse Event Reporting System for tisagenlecleucel
    Dores, Graca M.
    Jason, Christopher
    Niu, Manette T.
    Perez-Vilar, Silvia
    AMERICAN JOURNAL OF HEMATOLOGY, 2021, 96 (09) : 1087 - 1100
  • [36] An external facilitation intervention to increase uptake of an adverse drug event reporting intervention
    Lau, Erica Y.
    Small, Serena S.
    Butcher, Kate
    Cragg, Amber
    Loh, Gabriel W.
    Shalansky, Steve
    Hohl, Corinne M.
    FRONTIERS IN HEALTH SERVICES, 2023, 3
  • [37] Preventable adverse drug events in hospitalized patients: A comparative study of intensive care and general care units
    Cullen, DJ
    Sweitzer, BJ
    Bates, DW
    Burdick, E
    Edmondson, A
    Leape, LL
    CRITICAL CARE MEDICINE, 1997, 25 (08) : 1289 - 1297
  • [38] EPIDEMIOLOGY OF PREVENTABLE ADVERSE DRUG EVENTS IN MEDICAL AND SURGICAL INTENSIVE-CARE UNITS COMPARED TO GENERAL CARE UNITS
    CULLEN, DJ
    SWEITZER, BJ
    EDMONDSON, A
    BATES, DW
    LEAPE, LL
    ANESTHESIOLOGY, 1995, 83 (3A) : A214 - A214
  • [39] Evaluating the Impact of Black Box Warning Updates on the Reporting of Drug-Related Adverse Events: a Cross Sectional Study of the FAERS Database
    Yavne, Yarden
    Amar Shamir, Reut
    Shapiro, Michael
    Shepshelovich, Daniel
    EXPERT OPINION ON DRUG SAFETY, 2023, 22 (06) : 463 - 468
  • [40] Evaluating Ubrogepant-related adverse events using the FDA adverse event reporting system
    Cao, Bing
    Gu, Shanshan
    Shen, Zhisen
    Zhang, Yuna
    Shen, Yiming
    Chen, Hang
    EXPERT OPINION ON DRUG SAFETY, 2023, : 297 - 303